Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
SAN ANTONIO, July 3, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech's leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services.
The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide.
"Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials," said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan.
With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes.
Novotech's dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company's expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech's sustained growth trajectory is driven by its deep alignment with sponsors' evolving needs and its commitment to scientific excellence and operational agility.
"We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide," said Dr. John Moller, chief executive officer, Novotech
Novotech's unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets.
Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors.
Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Tarini Singh
E: [email protected]
About Novotech
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
32 minutes ago
- Cision Canada
Readout - Prime Minister Carney speaks with Prime Minister of Malaysia Anwar Ibrahim Français
OTTAWA, ON, July 3, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, spoke with the Prime Minister of Malaysia, Anwar Ibrahim. Prime Minister Carney and Prime Minister Anwar discussed the strong and dynamic trade relationship between Canada and Malaysia. They agreed to deepen bilateral co-operation in clean and conventional energy, cybersecurity, and artificial intelligence. The leaders look forward to meeting at the ASEAN Summit, under Malaysia's chairship. This document is also available at
Cision Canada
32 minutes ago
- Cision Canada
Prime Minister Carney speaks with President of the Philippines Ferdinand Marcos Jr. Français
OTTAWA, ON, July 3, 2025 /CNW/ - Today, the Prime Minister, Mark Carney, spoke with the President of the Philippines, Ferdinand Marcos Jr. The leaders discussed the close economic and cultural ties between Canada and the Philippines, with nearly one million Canadians of Filipino descent. They reflected on the Lapu-Lapu Day tragedy in Vancouver earlier this year and expressed their deep condolences to all those affected. Prime Minister Carney emphasized opportunities to deepen Canada's relationship with the Philippines in investment and commerce, including by advancing free trade. The two leaders agreed on the importance of a free and open Indo-Pacific, and of the efforts of both Canada and the Philippines to uphold the rules-based international order and security in the region. Prime Minister Carney extended an invitation to President Marcos Jr. to visit Canada. The leaders will remain in close contact. Canada-Philippines relations This document is also available at
Cision Canada
33 minutes ago
- Cision Canada
Federal and territorial governments invest in expansion to transit fleet in Whitehorse Français
WHITEHORSE, YT, July 3, 2025 /CNW/ - The City of Whitehorse will improve their transit system thanks to a combined investment of over $7.8 million from the federal and territorial governments. Ten 40-foot fully accessible buses will be added to the existing fleet in Whitehorse between 2026 and 2028. The City's current fleet consists of 15 low-floor accessible buses that were purchased between 2008 and 2023. New buses will ensure efficiency and maintain service levels while helping to meet the needs of the growing city for residents and visitors. The additional buses will allow opportunities to improve routes, ensure unexpected maintenance can be accommodated, and will maximize the service life of the fleet for the city. Quotes "Expanding the transit fleet in Whitehorse will provide people with more reliable and efficient service for their daily commuting and travel. By increasing accessibility, improving service levels and improving routes, our government is able to support a growing city with sustainable public transit infrastructure into the future." Dr. Brendan Hanley, Parliamentary Secretary to the Minister of Northern and Arctic Affairs and Member of Parliament for Yukon "Through this joint investment, we're delivering on our commitment to strengthen transit and active transportation options in partnership with the City of Whitehorse. Thank you to the Government of Canada for their continued support in building vibrant, sustainable, and connected Yukon communities." Richard Mostyn, Minister of Community Services "We are pleased to be working in partnership with the Governments of Canada and Yukon to bolster our transit fleet. Whitehorse is one of the fastest growing cities in Canada and enhancing public transit is key to ensuring the sustainable growth of our community. In recent years, our efforts to enhance transit services has led to record levels of ridership. This funding will ensure we can continue to build on that success and meet the growing needs of our community." Quick Facts The federal government is investing $5,894,443 through the Public Transit Infrastructure Stream of the Investing in Canada Infrastructure Program. The Government of Yukon is investing $1,965,481. Including today's announcement, eight infrastructure projects under the Public Transit Infrastructure Stream have been announced in the Yukon, with a total federal contribution of more than $9.8 million and a total territorial contribution of almost $3.3 million. The new Canada Public Transit Fund (CPTF) will provide an average of $3 billion a year of permanent funding to respond to local transit needs by enhancing integrated planning, improving access to public transit and active transportation, and supporting the development of more affordable, sustainable, and inclusive communities. The CPTF supports transit and active transportation investments in three streams: Metro Region Agreements, Baseline Funding, and Targeted Funding. Visit the Housing, Infrastructure and Communities Canada website for more information. Associated Links Public Transit Infrastructure Stream Housing and Infrastructure Project Map Strengthened Climate Plan Follow us on X, Facebook, Instagram and LinkedIn Web: Housing, Infrastructure and Communities Canada SOURCE Department of Housing, Infrastructure and Communities
